

## Disclosing material information.

<b>Date</b>	31/10/2024
<b>Name of the Listed Company</b>	Gulf Pharmaceutical Industries Julphar
<b>The Material Information</b>	The sale of Zahrat Al Rawdah Pharmacies LLC, a 100% subsidiary of Julphar's retail pharmacies and distribution division Planet Pharmacies LLC.
<b>The expected effect of material information on the financial position and results of the company's business and operations</b>	<p>The transaction includes the sale of Planet Pharmacies LLC's retail pharmacies operation in the Kingdom of Saudi Arabia. The business generated a revenue of SAR 367.9 million and net income of SAR 16.7 in 2023. Its net assets represent 9.1% of the consolidated total assets of the Julphar Group as of 31.06.2024.</p> <p>The transaction value amounts to SAR 444.1 million and will be paid in cash.</p> <p>The transaction is aligned with the company's strategic efforts to divest non-core assets and expand its portfolio into specialty pharma and innovative products in the MENA region. In addition, the company is exploring different strategic options for establishing the development and manufacturing of pipeline products in the Kingdom of Saudi Arabia.</p> <p>The transaction is subject to certain conditions and customary approvals. It is expected to be completed in the first quarter of 2025.</p>
<b>The financial period in which the financial impact is expected to appear</b>	Financial year 2025.

<b>The Name of the Authorized Signatory</b>	Basel Ziyadeh
<b>Designation</b>	CEO
<b>Signature and Date</b>	31/10/2024